Novo Nordisk received FDA approval for Rybelsus (semaglitude) tablets for control of blood sugar in adult patients with type 2 diabetes, along with diet and exercise.
Rybelsus is a glucagon-like peptide (GLP-1) receptor protein treatment approved in 7mg and 14 mg tablets for patients with type 2 diabetes. It is the first GLP-1 treatment approved in the U.S. that is not injected.
The FDA granted the approval based on the results of several clinical trials, including two placebo-controlled studies. Rybelsus as a stand-alone therapy resulted in a significant reduction in blood sugar compared with placebo.